The injectable form is more common and is often used for both diabetes and weight management
Section 1847A(i)(5) of the Act requires that for Part B rebatable drugs, as defined in section 1847A(i)(2)(A) of the Act, furnished on or after April 1, 2023, in quarters in which the payment amount described in section 1847A(i)(3)(A)(ii)(I) of the Act (or, in the case of selected drugs described under section 1192(c) of the Act, the payment amount described in section 1847A(b)(1)(B) of the Act), exceeds the inflation-adjusted payment amount determined in accordance with section 1847A(i)(3)(C) of the Act, the coinsurance will be 20 percent of the inflation-adjusted payment amount for such quarter (hereafter, the inflation-adjusted coinsurance amount)
Ligands, receptors, enzymes, and signaling intermediates are preserved when their structural relationships continue to permit reliable and energetically feasible function
STEP-1 Wilding 2021 NEJM : -14,9% a 2,4mg/68sem pour semaglutide vs -24,2% a 12mg/48sem pour retatrutide
Plan the move so you dont run out of medication mid-titration
Significant weight loss: Clinical trials have shown more weight loss compared to GLP-1 drugs alone